At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 104 enrolled
Drug / intervention
Vismodegib 150 mgdrug
Likely dose
Vismodegib 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pivotal Phase II, Multicenter, Single-arm, Two-cohort Trial Evaluating the Efficacy and Safety of GDC-0449 in Patients With Advanced Basal Cell Carcinoma
In Brief
A Phase 2 clinical trial evaluating Vismodegib 150 mg for Basal Cell Carcinoma. Completed, enrolled 104 participants across 36 sites in 6 countries.
Detailed Summary
This is a Phase II, single-arm, two-cohort multicenter clinical trial evaluating the efficacy and safety of vismodegib (GDC-0449) in patients with advanced basal cell carcinoma. All patients receive vismodegib until evidence of progression, intolerable toxicities most probably attributable to vismodegib, or withdrawal from the study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBasal Cell Carcinoma
CountriesAustralia, Belgium, France, Germany, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 2009
Enrollment StartFeb 2009
Primary CompletionNov 2010
Study CompletionApr 2014
TodayJul 2026
First PostedFeb 2, 2009
Enrollment StartFeb 10, 2009
Primary CompletionNov 26, 2010
Study CompletionApr 9, 2014
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 17.4 years ago
Interventions
Vismodegib 150 mgdrug
Vismodegib 150 mg was provided in hard gelatin capsules.